C-reactive protein and cardiovascular disease: a review of risk prediction and interventions (Q28192240)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article (publication date: March 2002)

Language	Label	Description	Also known as
English	C-reactive protein and cardiovascular disease: a review of risk prediction and interventions	scientific article (publication date: March 2002)

Statements

scholarly article

0 references

1 reference

Europe PubMed Central

C-reactive protein and cardiovascular disease: a review of risk prediction and interventions (English)

0 references

cardiovascular disease

1 reference

based on heuristic

inferred from title

Sarah D de Ferranti

1

object named as

Sarah de Ferranti

0 references

author name string

Nader Rifai

2

0 references

language of work or name

0 references

publication date

March 2002

0 references

Clinica Chimica Acta

0 references

317

0 references

1-2

0 references

1-15

0 references

Prevalence of nonfatal coronary heart disease among American adults

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Range of serum cholesterol values in the population developing coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Acute-phase proteins and other systemic responses to inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Complement activation by C-reactive protein complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Inflammation in cardiovascular disease: cart, horse, or both?

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Direct proinflammatory effect of C-reactive protein on human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Intravenous streptokinase treatment and serum C-reactive protein in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Enhanced inflammatory response in patients with preinfarction unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Independent prognostic value of elevated C-reactive protein in unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Comparison of the prognostic value of C-Reactive protein and troponin I in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Elevation of C-reactive protein in "active" coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Infections, inflammation, and the risk of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Hormone replacement therapy, inflammation, and hemostasis in elderly women

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Hormone replacement therapy and increased plasma concentration of C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Blood pressure and inflammation in apparently healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Retinal vein occlusion: C-reactive protein and arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Raised C-reactive protein levels in serum from smokers

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Lifetime Smoking Exposure Affects the Association of C-Reactive Protein with Cardiovascular Disease Risk Factors and Subclinical Disease in Healthy Elderly Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Elevated C-reactive protein levels in overweight and obese adults

2 references

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

based on heuristic

inferred from DOI database lookup

C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-α,in Vivo1

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Plasma Concentration of C-Reactive Protein and Risk of Developing Peripheral Vascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

C-Reactive Protein in Offspring Is Associated With the Occurrence of Myocardial Infarction in First-Degree Relatives

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900797-5

7 January 2021

Identifiers

10.1016/S0009-8981(01)00797-5

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28192240&oldid=2090605147"